

REMARKS

The Examiner has required restriction in the above-identified application and has divided the claims as follows:


- | | |
|-----------|---|
| Group I | Claims 1-19, drawn to compounds and compositions of Formula (I); |
| Group II | Claims 20-29, drawn to methods of use of compounds of Formula (I); |
| Group III | Claims 30-31, drawn to compounds of Formula II, |
| Group IV | Claim 32, drawn to a method of preparation of compounds of Formula I; |
| Group V | Claim 33-34, drawn to methods of preparation of compounds of
Formula II; and |
| Group VI | Claim 35-36, drawn to methods of preparation of compounds of
Formula IIa. |

Applicants elect Group I and elect example 147 in response to the requirement to elect a single species. Example 3a is a compound of formula (I) wherein B is a cyclohexyl; X is O; Z is -NH-; bond a is a single bond; R¹ is (phenylsulfonylmethyl); R² is (quinazolin-4-yl); R⁵ is isopropyl(methyl)amino; R¹⁰, R¹¹, R¹² and R¹³ are H; m is 0; and n is 1.

Rejoinder of the method of treating claims of Group II upon a finding of allowable compound claims of Group I is respectfully requested.

In view of the foregoing, Applicants submit that the application is now in condition for examination on the merits. Early notification of such action is requested.

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000



Mary K. VanAtten
Attorney for Applicant
Reg. No. 39,408
Phone: 609-252-4379
Date: December 13, 2005